Stent grafts with bioactive coatings

• US 20050021126A1
• Filed: 06/04/2004
• Published: 01/27/2005
• Est. Priority Date: 12/31/1998
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated, University of British Columbia
• Inventors: Hunter, William L., Machan, Lindsay S., Jackson, John K.
• Application Number:
  US10/862,019
• Publication Number:
  US 20050021126A1
• Time in Patent Office: Days
• US Class Current: 623/1.130
• CPC Class Codes: A61F 2/07 Stent-grafts
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2002/065 Y-shaped blood vessels
• CPC Class Codes: A61F 2002/075 the stent being loosely attached to the graft material, e.g. by stitching
• CPC Class Codes: A61F 2230/005 Rosette-shaped, e.g. star-shaped
• CPC Class Codes: A61F 2230/0054 V-shaped
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 2300/418 Agents promoting blood coagulation, blood-clotting agents, embolising agents
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft releases an agent which induces the in vivo adhesion of the stent graft to vessel walls, or, otherwise induces or accelerates an in vivo fibrotic reaction causing said stent graft to adhere to vessel wall. Also provided are methods for making and using such stent grafts.

Claims

1. A stent graft comprising an endoluminal stent and a graft, wherein said graft is comprised of a material which is not released and which induces or accelerates an in vivo fibrotic reaction causing said stent graft to adhere to vessel walls.

2. The stent graft according to claim 1 wherein said graft material comprises a vessel wall irritant.

3. The stent graft according to claim 1 wherein said graft material comprises a component of extracellular matrix.

4. The stent graft according to claim 1 wherein said graft material comprises polylysine or ethylenevinylacetate.

5. The stent graft according to claim 1 wherein said stent graft is bifurcated.

6. The stent graft according to claim 1 wherein said stent graft is a tube graft.

7. The stent graft according to claim 1 wherein said stent graft is cylindrical.

8. The stent graft according to claim 1 wherein said stent graft is self-expandable.

9. The stent graft according to claim 1 wherein said stent graft is balloon-expandable.

10. The stent graft according to claim 1 wherein said graft material further comprises a textile.

11. The stent graft according to claim 1 wherein said stent graft further comprises a coating that delays the onset of fibrosis.

12. The stent graft according to claim 1 wherein said stent graft is activated from a previously inactive stent graft to a stent graft that induces or accelerates an in vivo fibrotic reaction.

13. The stent graft according to claim 1 wherein the distal ends of said stent graft are adapted to release an agent that induces in vivo fibrosis.

14. The stent graft according to claim 13 wherein said agent comprises a vessel wall irritant.

15. The stent graft according to claim 14 wherein said vessel wall irritant is talcum powder.

16. The stent graft according to claim 14 wherein said vessel wall irritant is metallic beryllium.

17. The stent graft according to claim 14 wherein said vessel wall irritant is silica.

18. The stent graft according to claim 13 wherein said agent comprises a component of extracellular matrix.

19. The stent graft according to claim 13 wherein said agent is fibronectin.

20. The stent graft according to claim 13 wherein said agent is polylysine or ethylenevinylacetate.

21. The stent graft according to claim 13 wherein said agent is an inflammatory cytokine selected from the group consisting of TGFβ

, PDGF, VEGF, bFGF, TNFα

, NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone.

22. The stent graft according to claim 13 wherein said agent is an inflammatory microcrystal.

23. The stent graft according to claim 13 wherein said agent is N-carboxybutyl chitosan.

24. The stent graft according to claim 13 further comprising a coating at the distal ends of said stent graft to delay the onset of adhesion or fibrosis.

25. The stent graft according to claim 13 wherein said agent is first activated from a previously inactive agent to an active agent.

26. The stent graft according to claim 1 wherein the distal ends of said stent graft are adapted to release an agent that induces in vivo adhesion.

27. The stent graft according to claim 26 wherein said agent is an adhesive.

28. The stent graft according to claim 27 wherein said adhesive is cyanoacrylate.

29. The stent graft according to claim 26 further comprising a coating at the distal ends of said stent graft to delay the onset of adhesion or fibrosis.

30. The stent graft according to claim 26 wherein said agent is first activated from a previously inactive agent to an active agent.

31. A method for treating patient having an aneurysm, comprising delivering to a patient a stent graft comprising an endoluminal stent and a graft, wherein said graft is comprised of a material which is not released and which induces or accelerates an in vivo fibrotic reaction causing said stent graft to adhere to vessel walls, such that risk of rupture of the aneurysm is reduced.

32. The method according to claim 31 wherein said graft material comprises a vessel wall irritant.

33. The method according to claim 31 wherein said graft material comprises a component of extracellular matrix.

34. The method according to claim 31 wherein said graft material comprises polylysine or ethylenevinylacetate.

35. The method according to claim 31 wherein said stent graft is bifurcated.

36. The method according to claim 31 wherein said stent graft is a tube graft.

37. The method according to claim 31 wherein said stent graft is cylindrical.

38. The method according to claim 31 wherein said stent graft is self-expandable.

39. The method according to claim 31 wherein said stent graft is balloon-expandable.

40. The method according to claim 31 wherein said graft material further comprises a textile.

41. The method according to claim 31 wherein said stent graft further comprises a coating that delays the onset of fibrosis.

42. The method according to claim 31 wherein said aneurysm is an abdominal aortic aneurysm.

43. The method according to claim 31 wherein said aneurysm is a thoracic aortic aneurysm.

44. The method according to claim 31 wherein said aneurysm is an iliac aortic aneurysm.

45. The method according to claim 31 wherein said stent graft is activated from a previously inactive stent graft to a stent graft that induces or accelerates an in vivo fibrotic reaction.

46. The method according to claim 31 wherein the distal ends of said stent graft are adapted to release an agent that induces in vivo fibrosis.

47. The method according to claim 46 wherein said agent comprises a vessel wall irritant.

48. The method according to claim 47 wherein said vessel wall irritant is talcum powder.

49. The method according to claim 47 wherein said vessel wall irritant is metallic beryllium.

50. The method according to claim 47 wherein said vessel wall irritant is silica.

51. The method according to claim 46 wherein said agent comprises a component of extracellular matrix.

52. The method according to claim 46 wherein said agent is fibronectin.

53. The method according to claim 46 wherein said agent is polylysine or ethylenevinylacetate.

54. The method according to claim 46 wherein said agent is an inflammatory cytokine selected from the group consisting of TGFβ

, PDGF, VEGF, bFGF, TNFα

, NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone.

55. The method according to claim 46 wherein said agent is an inflammatory microcrystal.

56. The method according to claim 46 wherein said agent is N-carboxybutyl chitosan.

57. The method according to claim 46 further comprising a coating at the distal ends of said stent graft to delay the onset of adhesion or fibrosis.

58. The method according to claim 46 wherein said agent is first activated from a previously inactive agent to an active agent.

59. The method according to claim 31 wherein the distal ends of said stent graft are adapted to release an agent that induces in vivo adhesion.

60. The method according to claim 59 wherein said agent is an adhesive.

61. The method according to claim 60 wherein said adhesive is cyanoacrylate.

62. The method according to claim 59 further comprising a coating at the distal ends of said stent graft to delay the onset of adhesion or fibrosis.

63. The method according to claim 59 wherein said agent is first activated from a previously inactive agent to an active agent.